Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053017 | 1.00 | TSHR (0.50) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL407449 | 0.82 | TSHR (0.50) | TSHRHSD17B10VCAM1CA12CA2 | |
| SCHEMBL217250 | 0.78 | CA12 (0.52) | TSHRHSD17B10ALDH1A1CYP3A4CA12 | |
| SCHEMBL29449995 | 0.78 | CA12 (0.52) | TSHRHSD17B10ALDH1A1CYP3A4CA12 | |
| SCHEMBL825866 | 0.78 | VCAM1 (0.53) | TSHRHSD17B10ALDH1A1CYP3A4VCAM1 | |
| SCHEMBL11092340 | 0.77 | HSD17B10 (0.50) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL23271632 | 0.76 | CA12 (0.50) | TSHRHSD17B10ALDH1A1CYP3A4CA12 | |
| SCHEMBL28759539 | 0.76 | CA12 (0.50) | TSHRHSD17B10ALDH1A1CYP3A4CA12 | |
| Bromide SCHEMBL28616524 | 0.76 | CA12 (0.50) | TSHRHSD17B10ALDH1A1CYP3A4CA12 | |
| SCHEMBL34461940 | 0.76 | CA12 (0.50) | TSHRHSD17B10ALDH1A1CYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003343-A1 | KV7 MODULATORS | SANIONA A/S (DK) | 2025-01-02 | — | — | WO | disclosed |
| CN-117736222-A | MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures | 烨辉医药科技(上海)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| CN-106459048-A | Pyrazolopyridines and pyrazolopyrimidines | 辉瑞公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2066635-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-10 | — | — | EP | disclosed |
| CN-100469769-C | Benzyl-pyridazinons as reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (CH) | 2009-03-18 | — | — | CN | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| CN-1764649-A | Benzyl-pyridazinones as reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | TSHR 330/4885HSD17B10 4202/4885ALDH1A1 2993/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | TSHR 2852/4885HSD17B10 590/4885ALDH1A1 321/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | TSHR 85/4885HSD17B10 3689/4885ALDH1A1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.